OBJECTIVE Prostate cancer is one of the most commonly diagnosed cancers worldwide.Current therapies for metastatic prostate cancer are only marginally effective,and hence novel treatment modalities are urgently needed...OBJECTIVE Prostate cancer is one of the most commonly diagnosed cancers worldwide.Current therapies for metastatic prostate cancer are only marginally effective,and hence novel treatment modalities are urgently needed.Considerable evidence suggests that chronic inflammation plays a pivotal role in the development and progression of prostate cancer.Thus agents that can suppress these inflammatory mediators could form the basis of novel therapy for prostate cancer patients.In our study,we focused on analyzing the potential anticancer effects of nimbolide,a terpenoid lactone derived from Azadirachta indica(Neem tree)against prostate cancer.METHODS Molecular biology techniques such as western blot analysis,DNA binding,luciferase assays,and immunohistochemistry were used for both in vitro and in vivo experiments.RESULTS Data from the in vitrostudies indicated that nimbolide could inhibit cell proliferation,induce apoptosis and suppress cellular invasion and migration.Interestingly,nimbolide also abrogated the activation of pro-inflammatory STAT 3 transcription factor,and this effect was found to be mediated via an increased production of reactive oxygen species(ROS),whereas depletion of ROS attenuated pSTAT 3 inhibitory effects of the drug.The in vivo efficacy of nimbolide was also noted in transgenic adenocarcinoma of mouse prostate(TRAMP)model,in which this triterpenoid significantly suppressed the tumor progression and growth without exhibiting any substantial adverse effects.CONCLUSION Overall our findings indicate that nimbolide exhibits significant anticancer effects in prostate cancer,and these effects may be mediated at least in part through the modulation of STAT 3 signaling pathway.展开更多
Background and objective Bone metastases (BM) are the primary cause of morbidity and mortality of prostate cancer (PCa) and noeective therapy is currently available.
前列腺癌是全球男性最常见的恶性肿瘤之一,严重危害男性身体健康。自前列腺特异性膜抗原(prostate specific membrane antigen,PSMA)被证实是诊断前列腺癌的首选标志物,PSMA靶向放射性药物在前列腺癌诊治中取得显著进展,有效提高了前列...前列腺癌是全球男性最常见的恶性肿瘤之一,严重危害男性身体健康。自前列腺特异性膜抗原(prostate specific membrane antigen,PSMA)被证实是诊断前列腺癌的首选标志物,PSMA靶向放射性药物在前列腺癌诊治中取得显著进展,有效提高了前列腺癌的诊断灵敏度与治疗效果。文章就近年来PSMA靶向放射性分子探针的相关研究进展进行综述,分析探针结构设计理念并总结临床经验,以期对前列腺癌放射性诊疗分子探针的开发有所裨益。展开更多
目的探讨外周血前列腺癌抗原3(prostate cancer antigen 3,PCA3)基因表达在前列腺癌早期诊断中的应用。方法选取2015年10月至2016年12月因前列腺疾病于本院初次就诊的患者以及健康体检者共120例男性为研究对象。其中确诊前列腺癌46例(...目的探讨外周血前列腺癌抗原3(prostate cancer antigen 3,PCA3)基因表达在前列腺癌早期诊断中的应用。方法选取2015年10月至2016年12月因前列腺疾病于本院初次就诊的患者以及健康体检者共120例男性为研究对象。其中确诊前列腺癌46例(局限性前列腺癌27例、非局限性前列腺癌19例),前列腺增生40例,前列腺炎24例,健康体检者10例。采用实时荧光定量PCR技术(Taqman探针)检测研究对象外周血中PCA3 mRNA的模板数,比较其在不同组别中的表达含量,探讨其与前列腺癌诊断的相关性。结果 PCA3基因仅在前列腺癌组(31/46)和前列腺增生组(4/40)中表达,在其余组中均未见表达;非局限性前列腺癌组患者外周血PCA3基因表达量显著高于局限性前列腺癌组(P<0.001)。结论 PCA3基因是前列腺癌的特异性肿瘤标志物,外周血PCA3基因检测有助于前列腺癌的早期诊断。展开更多
基金The project supported by agrant from NUS Academic Research Fund
文摘OBJECTIVE Prostate cancer is one of the most commonly diagnosed cancers worldwide.Current therapies for metastatic prostate cancer are only marginally effective,and hence novel treatment modalities are urgently needed.Considerable evidence suggests that chronic inflammation plays a pivotal role in the development and progression of prostate cancer.Thus agents that can suppress these inflammatory mediators could form the basis of novel therapy for prostate cancer patients.In our study,we focused on analyzing the potential anticancer effects of nimbolide,a terpenoid lactone derived from Azadirachta indica(Neem tree)against prostate cancer.METHODS Molecular biology techniques such as western blot analysis,DNA binding,luciferase assays,and immunohistochemistry were used for both in vitro and in vivo experiments.RESULTS Data from the in vitrostudies indicated that nimbolide could inhibit cell proliferation,induce apoptosis and suppress cellular invasion and migration.Interestingly,nimbolide also abrogated the activation of pro-inflammatory STAT 3 transcription factor,and this effect was found to be mediated via an increased production of reactive oxygen species(ROS),whereas depletion of ROS attenuated pSTAT 3 inhibitory effects of the drug.The in vivo efficacy of nimbolide was also noted in transgenic adenocarcinoma of mouse prostate(TRAMP)model,in which this triterpenoid significantly suppressed the tumor progression and growth without exhibiting any substantial adverse effects.CONCLUSION Overall our findings indicate that nimbolide exhibits significant anticancer effects in prostate cancer,and these effects may be mediated at least in part through the modulation of STAT 3 signaling pathway.
文摘Background and objective Bone metastases (BM) are the primary cause of morbidity and mortality of prostate cancer (PCa) and noeective therapy is currently available.
文摘前列腺癌是全球男性最常见的恶性肿瘤之一,严重危害男性身体健康。自前列腺特异性膜抗原(prostate specific membrane antigen,PSMA)被证实是诊断前列腺癌的首选标志物,PSMA靶向放射性药物在前列腺癌诊治中取得显著进展,有效提高了前列腺癌的诊断灵敏度与治疗效果。文章就近年来PSMA靶向放射性分子探针的相关研究进展进行综述,分析探针结构设计理念并总结临床经验,以期对前列腺癌放射性诊疗分子探针的开发有所裨益。
